Clorhexidine Versus Povidone for the Prevention of Surgical Site Infection After Cesarean Section
Clorhexidine Versus Povidone for the Prevention of Surgical Site Infection in Patients After Cesarean Section. Randomized, Controlled Trial.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Panama, Panama
- Saint Thomas Maternity Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Gestational age > 32 weeks
- Emergency cesarean section
Exclusion Criteria:
- Allergy to clorhexidine
- Allergy to povidone
- Evidence of infection in the surgical site
- Loss to follow up at 15 days
- Surgeries that due to the emergency of the case do not allow the five minutes of skin cleaning.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Clorhexidine
Skin prior to the surgical incision will be cleaned for five minutes with Clorhexidine.
|
Cleaning of the surgical site previous to the incision with a clorhexidine solution for five minutes.
|
|
Experimental: Povidone
Skin prior to surgical incision will be cleaned for five minutes with a povidine solution.
|
Cleaning of the surgical site previous to the incision with a povidone solution for five minutes.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Surgical Site infection (SSI)
Time Frame: 3 days
|
The patients will be evaluated for evidence of surgical site infection before leaving the hospital, three (3) days after surgery.
The presence of fever, suppurative secretion through the wound or cutaneous changes compatible witn infection will be considered a surgical site infection (SSI).
This outcome will be evaluated with a qualitative variable (presence of SSI).
The patients will be classified in accordance as "With SSI" or "Without SSI".
|
3 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hospitalization
Time Frame: 15 days
|
The patients will be evaluated for evidence of surgical site infection 15 days post surgery.
The need to admit the patient to the hospital for management of a surgical site infection will be classified with "Hospitalization - Yes/No".
|
15 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MHST2012-04
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.